Table 1.

Multivariate analysis of baseline and day 7 PET findings on clinical outcomes landmarked from day 14 of induction therapy: OS, PFS, and CRD

	Excluding GEP variables			Including GEP variables
Variable	n/N (%)	HR (95% CI)	P value	n/N (%)	HR (95% CI)	P value
OS
GEP70 high risk				52/277 (19%)	4.10 (2.57-6.52)	<.001
Baseline MBS OL >2	96/302 (32%)	1.82 (1.17-2.83)	.008	86/277 (31%)	1.81 (1.16-2.85)	.010
Day-7 PET FL >3	81/302 (27%)	1.86 (1.19-2.91)	.006	75/277 (27%)	1.67 (1.05-2.65)	.030
Age ≥65 years	78/302 (26%)	1.79 (1.16-2.76)	.008	72/277 (26%)	1.81 (1.16-2.83)	.009
Cytogenetic abnormalities	109/302 (36%)	2.15 (1.40-3.30)	<.001
B2M >5.5 mg/L	73/302 (24%)	1.95 (1.25-3.03)	.003
PFS
GEP70 high risk				52/277 (19%)	3.23 (2.09-4.99)	<.001
Day 7 PET FL >3	81/302 (27%)	1.83 (1.23-2.71)	.003	75/277 (27%)	1.81 (1.21-2.70)	.004
B2M >5.5 mg/L	73/302 (24%)	1.82 (1.19-2.77)	.005	66/277 (24%)	1.60 (1.05-2.45)	.030
LDH ≥190 U/L	75/302 (25%)	1.69 (1.12-2.53)	.012
CA13	57/302 (19%)	1.75 (1.13-2.71)	.012
Albumin <3.5 g/dL	107/302 (35%)	1.60 (1.07-2.37)	.021
CRD
GEP-70 high risk				28/180 (16%)	3.61 (1.93-6.77)	<.001
B2M >5.5 mg/L	39/196 (20%)	3.77 (2.11-6.75)	<.001	36/180 (20%)	2.89 (1.56-5.37)	<.001
CA13	40/196 (20%)	1.98 (1.07-3.67)	.030

Model selection and estimates based on the set of patients with complete data for the variables examined. P value from Wald χ-square test in Cox regression. Variables considered: age ≥65 years, albumin <3.5 g/dL, B2M ≥3.5 mg/L, B2M >5.5 mg/L, creatinine ≥2.0 mg/dL, C-reactive protein ≥8 mg/L, hemoglobin <10 g/dL, LDH ≥190 U/L, cytogenetic abnormalities, CA13, hypodiploid, CA 13/hypodiploid, GEP70 high risk, GEP Proliferation Index ≥10, GEP Centrosome Index ≥3, GEP Molecular Subgroup, baseline MBS OL (>0, >2), baseline MRI FL (>0, >7), baseline PET FL (>0, >3), baseline PET EMD, day 7 PET FL (>0, >3).

GEP, gene expression profiling; HR, hazard ratio; LDH, Lactate dehydrogenase